TLPH

0.78526.25%
VJ

Vincent J. Angotti

CEO & Director

Mr. Vincent J. Angotti, also known as Vince, has been the Chief Executive Officer of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since March 6, 2017. Mr. Angotti served as the Chief Executive Officer of Xenoport, Inc. since October 1, 2015 and served as its Chief Operating Officer and Executive Vice President from June 4, 2012 to October 1, 2015. He served as Acting Chief Financial Officer of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) from June 2, 2017 to August 16, 2017. Mr. Angotti served as the Chief Commercialization Officer and Senior Vice President of Xenoport, Inc. from May 1, 2008 to June 4, 2012. During his tenure at XenoPort, Mr. Angotti was involved in the re-acquisition of Horizant from GSK and implemented a successful re-branding and re-launch strategy leading to XenoPort's acquisition by Arbor Pharmaceuticals, LLC in 2016. He has sales and marketing experience in both large and specialty pharmaceutical businesses. Mr. Angotti served as the Senior Vice President of Sales and Marketing at Reliant Pharmaceuticals, Inc., since October 2006, where he held several positions from January 2001 to 2008. He served as Vice President of Sales and Marketing of Reliant from June 2006 to October 2006, Vice President of Sales from October 2002 to June 2006 and as its Executive Director of Sales from January 2001 to October 2002. While at Reliant, he led the expansion of a mass market and specialty sales force in the United States to promote both Lovaza, a treatment for hypertriglyceridemia and Rythmol SR. In addition, he launched co-promotion partnerships with Biovail Corporation and Amylin Pharmaceuticals, Inc. and oversaw marketing, sales, managed markets, operations and forecasting functions. Mr. Angotti served at Novartis AG (Novartis Pharmaceuticals Corp.) from 1991 to January 2001 and oversaw sales, sales management, operations and training and development. He served as Executive Director of Sales Operations of Novartis and was responsible for daily operations as well as for the mass market sales force expansions, field force productivity and effectiveness and Contract Sales Organizations. He has been a Director of Talphera, Inc. (formerly known as AcelRx Pharmaceuticals, Inc.) since March 6, 2017. He served as a Director of Xenoport, Inc. since October 1, 2015. Mr. Angotti has a Bachelor of Science degree from Cornell University in Business Management in 1990 and as an M.B.A. from Columbia University in 2000.

Positions